Publications by authors named "Agustin Rivero"
Article Synopsis
- Respiratory syncytial virus (RSV) is a serious infectious disease with significant health, social, and economic impacts, prompting the need for effective preventive measures, such as the newly approved nirsevimab for infants.
- A novel multi-criteria decision analysis (MCDA) framework was developed to evaluate the effectiveness of nirsevimab compared to a placebo, incorporating insights from a panel of nine experts.
- The findings indicate that nirsevimab holds considerable value for RSV prevention in Spain, showcasing high efficacy, potential cost savings for healthcare, and promoting public health awareness while addressing health disparities.
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Int J Technol Assess Health Care
August 2022
Objectives: Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA).
Methods: Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time.